Movatterモバイル変換


[0]ホーム

URL:


BR9914772A - Set of genetic elements, vector, host cell, set for the production of a nucleic acid sequence, method for in vivo or in vitro production of a nucleic acid sequence, cdna transcription, inhibitor nucleic acid molecule, mrna transcription, heteroduplex molecule and pharmaceutical composition - Google Patents

Set of genetic elements, vector, host cell, set for the production of a nucleic acid sequence, method for in vivo or in vitro production of a nucleic acid sequence, cdna transcription, inhibitor nucleic acid molecule, mrna transcription, heteroduplex molecule and pharmaceutical composition

Info

Publication number
BR9914772A
BR9914772ABR9914772-6ABR9914772ABR9914772ABR 9914772 ABR9914772 ABR 9914772ABR 9914772 ABR9914772 ABR 9914772ABR 9914772 ABR9914772 ABR 9914772A
Authority
BR
Brazil
Prior art keywords
nucleic acid
vector
production
acid sequence
cdna
Prior art date
Application number
BR9914772-6A
Other languages
Portuguese (pt)
Inventor
Charles A Conrad
Michael J Skillern
Jonathan F Elliston
Original Assignee
Ingene Inc
Cytogenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ingene Inc, Cytogenix IncfiledCriticalIngene Inc
Publication of BR9914772ApublicationCriticalpatent/BR9914772A/en

Links

Classifications

Landscapes

Abstract

Translated fromPortuguese

"CONJUNTO DE ELEMENTOS GENéTICOS, VETOR, CéLULAHOSPEDEIRA, CONJUNTO PARA A PRODUçãO DE UMASEQUêNCIA DE áCIDO NUCLéICO, MéTODO PARA APRODUçãO IN VIVO OU IN VITRO DE UMA SEQUêNCIA DEáCIDO NUCLéICO, TRANSCRIçãO DE CDNA, MOLéCULA DEáCIDO NUCLéICO INIBIDOR, TRANSCRIçãO DE MRNA,MOLéCULA HETERODUPLEX E COMPOSIçãOFARMACêUTICA". A presente invenção se refere a métodos ecomposições para a produção de cDNA de cordão único(ss-cDNA) com um sistema à base de vetores era célulaseucarióticas. O vetor contem todas as instruções de sinalização efunções enzimáticas para permitir à célula hospedeira produzir oss-cDNA codificando uma seq³ência de ácido nucléico desejada(uma "seq³ência de interesse"). Estão descritos os componentesincluídos no vetor para a sintetização do ss-cDNA in vivo. Osmesmos incluem (1) uma gene de transcriptase reversa; (2) umelemento genético o qual fornece o templato para a seq³ência deinteresse ssDNA desejada; e (3) um segundo elemento genéticolocalizado próximo ao elemento genético codificando a seq³ênciade interesse o qual fornece o local de ligação prímero para atranscrição reversa pela molécula de transcriptase reversa. O vetortambém contem promotor(es)/ reforçador(es) apropriados. Tambémé descrito aqui um método para a construção de uma vetorincluindo estes componentes."SET OF GENETIC ELEMENTS, VECTOR, PHONE CELLS, SET FOR THE PRODUCTION OF A NUCLEIC ACID HUMIDITY, METHOD FOR IN VIVO OR IN VITRO NUCLEIC ACID, KNOWLEDGE, KNOWLEDGE, KNOWLEDGE, KNOWLEDGE TRANSACTION, PHARMACEUTICAL COMPOSITION ". The present invention relates to methods and compositions for the production of single-stranded cDNA (ss-cDNA) with a cell-based eukaryotic vector system. The vector contains all signaling instructions and enzymatic functions to allow the host cell to produce oss-cDNA encoding a desired nucleic acid sequence (a "sequence of interest"). The components included in the vector for the synthesis of ss-cDNA in vivo are described. Osmesms include (1) a reverse transcriptase gene; (2) a genetic element which provides the template for the desired ssDNA interest sequence; and (3) a second genetic element located next to the genetic element encoding the sequence of interest which provides the primary binding site for reverse transcription by the reverse transcriptase molecule. The vector also contains appropriate promoter (s) / enhancer (s). Also described here is a method for constructing a vector including these components.

BR9914772-6A1998-10-091999-10-12 Set of genetic elements, vector, host cell, set for the production of a nucleic acid sequence, method for in vivo or in vitro production of a nucleic acid sequence, cdna transcription, inhibitor nucleic acid molecule, mrna transcription, heteroduplex molecule and pharmaceutical compositionBR9914772A (en)

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
US16979398A1998-10-091998-10-09
US39778399A1999-09-161999-09-16
PCT/US1999/023933WO2000022113A1 (en)1998-10-091999-10-12ENZYMATIC SYNTHESIS OF ssDNA

Publications (1)

Publication NumberPublication Date
BR9914772Atrue BR9914772A (en)2001-12-11

Family

ID=26865381

Family Applications (1)

Application NumberTitlePriority DateFiling Date
BR9914772-6ABR9914772A (en)1998-10-091999-10-12 Set of genetic elements, vector, host cell, set for the production of a nucleic acid sequence, method for in vivo or in vitro production of a nucleic acid sequence, cdna transcription, inhibitor nucleic acid molecule, mrna transcription, heteroduplex molecule and pharmaceutical composition

Country Status (9)

CountryLink
EP (1)EP1117776A1 (en)
JP (1)JP2002527061A (en)
KR (1)KR20010099682A (en)
AU (1)AU6430599A (en)
BR (1)BR9914772A (en)
CA (1)CA2346155A1 (en)
IL (1)IL142490A0 (en)
MX (1)MXPA01003642A (en)
WO (1)WO2000022113A1 (en)

Families Citing this family (184)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
DE19956568A1 (en)1999-01-302000-08-17Roland Kreutzer Method and medicament for inhibiting the expression of a given gene
US7419964B2 (en)*1999-09-162008-09-02Cytogenix, Inc.Treatment of HSV-related pathologies using ssDNA
EP1222259A1 (en)*1999-10-042002-07-17Cytogenix, Inc.ALTERING GENE EXPRESSION WITH ssDNA PRODUCED IN VIVO
DE10100586C1 (en)2001-01-092002-04-11Ribopharma AgInhibiting gene expression in cells, useful for e.g. treating tumors, by introducing double-stranded complementary oligoRNA having unpaired terminal bases
US7767802B2 (en)2001-01-092010-08-03Alnylam Pharmaceuticals, Inc.Compositions and methods for inhibiting expression of anti-apoptotic genes
US7423142B2 (en)2001-01-092008-09-09Alnylam Pharmaceuticals, Inc.Compositions and methods for inhibiting expression of anti-apoptotic genes
US7745418B2 (en)2001-10-122010-06-29Alnylam Pharmaceuticals, Inc.Compositions and methods for inhibiting viral replication
AU2002363997A1 (en)*2001-12-142003-06-30Yale UniversityIntracellular generation of single-stranded dna
EP2636739B1 (en)2004-03-122014-12-10Alnylam Pharmaceuticals Inc.iRNA agents targeting VEGF
AU2005290337A1 (en)*2004-09-282006-04-06Cytogenix, Inc.Single-stranded antimicrobial oligonucleotides and uses thereof
WO2007056331A2 (en)2005-11-092007-05-18Alnylam Pharmaceuticals, Inc.Compositions and methods for inhibiting expression of factor v leiden mutant gene
US8658608B2 (en)2005-11-232014-02-25Yale UniversityModified triple-helix forming oligonucleotides for targeted mutagenesis
KR101362681B1 (en)2006-03-312014-02-13알닐람 파마슈티칼스 인코포레이티드Compositions and methods for inhibiting expression of Eg5 gene
WO2007127919A2 (en)2006-04-282007-11-08Alnylam Pharmaceuticals, Inc.Compositions and methods for inhibiting expression of a gene from the jc virus
CA2651839C (en)2006-05-112016-02-09Alnylam Pharmaceuticals, Inc.Compositions and methods for inhibiting expression of the pcsk9 gene
JP2009537153A (en)2006-05-192009-10-29アルニラム ファーマシューティカルズ, インコーポレイテッド Aha RNAi regulation and its therapeutic use
EP2018443A4 (en)2006-05-222009-11-11Alnylam Pharmaceuticals IncCompositions and methods for inhibiting expression of ikk-b gene
CA2663803A1 (en)2006-09-182008-03-27Alnylam Pharmaceuticals, Inc.Rnai modulation of scap and therapeutic uses thereof
AU2007299629C1 (en)2006-09-212012-05-10Alnylam Pharmaceuticals, Inc.Compositions and methods for inhibiting expression of the HAMP gene
PE20090064A1 (en)2007-03-262009-03-02Novartis Ag DOUBLE-CHAIN RIBONUCLEIC ACID TO INHIBIT THE EXPRESSION OF THE HUMAN E6AP GENE AND THE PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
CA2692503C (en)2007-07-052013-09-24Novartis AgDsrna for treating viral infection
AU2008335202A1 (en)2007-12-102009-06-18Alnylam Pharmaceuticals, Inc.Compositions and methods for inhibiting expression of Factor VII gene
BRPI0909779A2 (en)2008-03-052019-09-24Alnylam Pharmaceuticals Inc compositions and processes for inhibiting the expression of eg5 and vegf genes
US8318693B2 (en)2008-09-022012-11-27Alnylam Pharmaceuticals, Inc.Compositions and methods for inhibiting expression of mutant EGFR gene
US8546554B2 (en)2008-09-252013-10-01Alnylam Pharmaceuticals, Inc.Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene
ES2656516T3 (en)2008-10-202018-02-27Alnylam Pharmaceuticals, Inc. Compositions and methods to inhibit the expression of transthyretin
CA2746514C (en)2008-12-102018-11-27Alnylam Pharmaceuticals, Inc.Gnaq targeted dsrna compositions and methods for inhibiting expression
CA2750459A1 (en)2009-02-032010-08-12F. Hoffmann-La Roche AgCompositions and methods for inhibiting expression of ptp1b genes
WO2010099341A1 (en)2009-02-262010-09-02Alnylam Pharmaceuticals, Inc.Compositions and methods for inhibiting expression of mig-12 gene
WO2010105209A1 (en)2009-03-122010-09-16Alnylam Pharmaceuticals, Inc.LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
WO2010148013A2 (en)2009-06-152010-12-23Alnylam Pharmaceuticals, Inc.Lipid formulated dsrna targeting the pcsk9 gene
US9051567B2 (en)2009-06-152015-06-09Tekmira Pharmaceuticals CorporationMethods for increasing efficacy of lipid formulated siRNA
US20110112176A1 (en)2009-11-092011-05-12John Frederick BoylanCompositions and methods for inhibiting expression of kif10 genes
US20110152349A1 (en)2009-12-182011-06-23Anke GeickCompositions and methods for inhibiting expression of il-18 genes
US20110196016A1 (en)2010-02-052011-08-11Anke GeickCompositions and Methods for Inhibiting Expression of IKK2 Genes
CA2792291A1 (en)2010-03-292011-10-06Kumamoto UniversitySirna therapy for transthyretin (ttr) related ocular amyloidosis
US8507663B2 (en)2010-04-062013-08-13Alnylam Pharmaceuticals, Inc.Compositions and methods for inhibiting expression of CD274/PD-L1 gene
WO2011153323A2 (en)2010-06-022011-12-08Alnylam Pharmaceuticals, Inc.Compositions and methods directed to treating liver fibrosis
WO2012052258A1 (en)2010-10-182012-04-26Arrowhead Research CorporationCompositions and methods for inhibiting expression of rrm2 genes
US9193973B2 (en)2010-12-102015-11-24Alynylam Pharmaceuticals, Inc.Compositions and methods for increasing erythropoietin (EPO) production
WO2012079046A2 (en)2010-12-102012-06-14Alnylam Pharmaceuticals, Inc.Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
RU2702501C2 (en)2011-03-292019-10-08Элнилэм Фармасьютикалз, Инк.Compositions and methods for inhibiting tmprss6 gene expression
WO2012177906A1 (en)2011-06-212012-12-27Alnylam Pharmaceuticals, Inc.Assays and methods for determining activity of a therapeutic agent in a subject
KR102232287B1 (en)2011-06-212021-03-29알닐람 파마슈티칼스 인코포레이티드Angiopoietin-like 3(angptl3) irna compostions and methods of use thereof
KR102540778B1 (en)2011-06-212023-06-07알닐람 파마슈티칼스 인코포레이티드Compositions and methods for inhibition of expression of apolipoprotein c-iii(apoc3) genes
US9228188B2 (en)2011-06-212016-01-05Alnylam Pharmaceuticals, Inc.Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression
US9068184B2 (en)2011-06-212015-06-30Alnylam Pharmaceuticals, Inc.Compositions and methods for inhibition of expression of protein C (PROC) genes
WO2012178033A2 (en)2011-06-232012-12-27Alnylam Pharmaceuticals, Inc.Serpina1 sirnas: compositions of matter and methods of treatment
TWI695066B (en)2011-06-302020-06-01美商艾羅海德製藥公司Compositions and methods for inhibiting gene expression of hepatitis b virus
WO2013019857A2 (en)2011-08-012013-02-07Alnylam Pharmaceuticals, Inc.Method for improving the success rate of hematopoietic stem cell transplants
US9133461B2 (en)2012-04-102015-09-15Alnylam Pharmaceuticals, Inc.Compositions and methods for inhibiting expression of the ALAS1 gene
US9127274B2 (en)2012-04-262015-09-08Alnylam Pharmaceuticals, Inc.Serpinc1 iRNA compositions and methods of use thereof
MX367076B (en)2012-12-052019-08-05Alnylam Pharmaceuticals IncPCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF.
WO2014130922A1 (en)2013-02-252014-08-28Trustees Of Boston UniversityCompositions and methods for treating fungal infections
MX360560B (en)2013-03-132018-11-07Geneweave Biosciences IncNon-replicative transduction particles and transduction particle-based reporter systems.
SG10201912286TA (en)2013-03-142020-02-27Alnylam Pharmaceuticals IncCOMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP2978446B1 (en)2013-03-272020-03-04The General Hospital CorporationAnti-cd33 antibody for use in treating alzheimer's disease
AR096203A1 (en)2013-05-062015-12-16Alnylam Pharmaceuticals Inc DOSAGES AND METHODS FOR MANAGING NUCLEIC ACID MOLECULES FORMULATED IN LIPIDS
SI2999785T1 (en)2013-05-222018-08-31Alnylam Pharmaceuticals, Inc.Serpina1 irna compositions and methods of use thereof
EP3587578A1 (en)2013-05-222020-01-01Alnylam Pharmaceuticals, Inc.Tmprss6 irna compositions and methods of use thereof
CN109536493A (en)2013-10-022019-03-29阿尔尼拉姆医药品有限公司For inhibiting the composition and method of LECT2 gene expression
EP3052107B1 (en)2013-10-042018-05-02Novartis AGOrganic compounds to treat hepatitis b virus
EP3052627B1 (en)2013-10-042018-08-22Novartis AGNovel formats for organic compounds for use in rna interference
CN105683163B (en)2013-10-042018-11-09诺华股份有限公司3 ' end caps of the RNAi agent used in RNA interference
MX390724B (en)2013-10-042025-03-21Alnylam Pharmaceuticals IncCompositions and methods for inhibiting expression of the alas1 gene
EA201691215A1 (en)2013-12-122016-11-30Элнилэм Фармасьютикалз, Инк. COMPOSITIONS ON THE BASIS OF IRNA TO THE COMPONENT OF THE COMPLEX AND METHODS OF THEIR APPLICATION
CN106103718B (en)2014-02-112021-04-02阿尔尼拉姆医药品有限公司 Hexokinase (KHK) iRNA compositions and methods of use
WO2015175510A1 (en)2014-05-122015-11-19Alnylam Pharmaceuticals, Inc.Methods and compositions for treating a serpinc1-associated disorder
CN112852809A (en)2014-05-222021-05-28阿尔尼拉姆医药品有限公司Angiotensinogen (AGT) iRNA compositions and methods of use thereof
JOP20200115A1 (en)2014-10-102017-06-16Alnylam Pharmaceuticals IncCompositions And Methods For Inhibition Of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
JOP20200092A1 (en)2014-11-102017-06-16Alnylam Pharmaceuticals IncHEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2016081444A1 (en)2014-11-172016-05-26Alnylam Pharmaceuticals, Inc.Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
AU2016219263B2 (en)2015-02-132022-12-01Alnylam Pharmaceuticals, Inc.Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
EP3283631A1 (en)2015-04-132018-02-21Alnylam Pharmaceuticals, Inc.Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
KR20250107273A (en)2015-05-062025-07-11알닐람 파마슈티칼스 인코포레이티드Factor XII (Hageman Factor) (F12), KALLIKREIN B, PLASMA (FLETCHER FACTOR) 1 (KLKB1), and Kininogen 1 (KNG1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP3307316A1 (en)2015-06-122018-04-18Alnylam Pharmaceuticals, Inc.Complement component c5 irna compositions and methods of use thereof
WO2016209862A1 (en)2015-06-232016-12-29Alnylam Pharmaceuticals, Inc.Glucokinase (gck) irna compositions and methods of use thereof
WO2017011286A1 (en)2015-07-102017-01-19Alnylam Pharmaceuticals, Inc.Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
EP3332007A4 (en)2015-08-072019-07-17Arrowhead Pharmaceuticals, Inc. RNA INTERFERENCE THERAPY FOR HEPATITIS B VIRUS INFECTION
JP7028764B2 (en)2015-09-022022-03-02アルナイラム ファーマシューティカルズ, インコーポレイテッド Programmed cell death 1 Ligand 1 (PD-L1) iRNA composition and its usage
WO2017048843A1 (en)2015-09-142017-03-23Alnylam Pharmaceuticals, Inc.Compositions and methods for inhibiting expression of the alas1 gene
MX2018006989A (en)2015-12-072018-09-05Genzyme CorpMethods and compositions for treating a serpinc1-associated disorder.
JP2018536689A (en)2015-12-102018-12-13アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof
WO2017143042A2 (en)2016-02-162017-08-24Yale UniversityCompositions for enhancing targeted gene editing and methods of use thereof
MA45295A (en)2016-04-192019-02-27Alnylam Pharmaceuticals Inc HIGH DENSITY LIPOPROTEIN BINDING PROTEIN (HDLBP / VIGILINE) RNA COMPOSITION AND METHODS FOR USING THEM
US20190256845A1 (en)2016-06-102019-08-22Alnylam Pharmaceuticals, Inc.COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
JOP20170161A1 (en)2016-08-042019-01-30Arrowhead Pharmaceuticals IncRNAi Agents for Hepatitis B Virus Infection
TWI788312B (en)2016-11-232023-01-01美商阿尼拉製藥公司SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
TWI865997B (en)2016-12-162024-12-11美商阿尼拉製藥公司METHODS FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES USING TRANSTHYRETIN (TTR) iRNA COMPOSITIONS
US20200113821A1 (en)2017-04-042020-04-16Yale UniversityCompositions and methods for in utero delivery
TWI801377B (en)2017-04-182023-05-11美商阿尼拉製藥公司Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
TW202434265A (en)2017-07-102024-09-01美商健贊公司Methods and compositions for treating a bleeding event in a subject having hemophilia
WO2019014530A1 (en)2017-07-132019-01-17Alnylam Pharmaceuticals Inc.Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof
WO2019089922A1 (en)2017-11-012019-05-09Alnylam Pharmaceuticals, Inc.Complement component c3 irna compositions and methods of use thereof
US20200385719A1 (en)2017-11-162020-12-10Alnylam Pharmaceuticals, Inc.Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
EP3714054A1 (en)2017-11-202020-09-30Alnylam Pharmaceuticals, Inc.Serum amyloid p component (apcs) irna compositions and methods of use thereof
JP2021508491A (en)2017-12-182021-03-11アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. High Mobility Group Box-1 (HMGB1) iRNA Composition and How to Use It
US11008602B2 (en)2017-12-202021-05-18Roche Molecular Systems, Inc.Non-replicative transduction particles and transduction particle-based reporter systems
TWI851574B (en)2018-05-142024-08-11美商阿尼拉製藥公司ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2020037125A1 (en)2018-08-162020-02-20Alnylam Pharmaceuticals Inc.Compositions and methods for inhibiting expression of the lect2 gene
CA3105385A1 (en)2018-09-182020-03-26Alnylam Pharmaceuticals, Inc.Ketohexokinase (khk) irna compositions and methods of use thereof
CN113166760A (en)2018-11-232021-07-23赛诺菲 Novel RNA compositions and methods for inhibiting ANGPTL8
US20220090094A1 (en)2018-12-272022-03-24Roche Molecular Systems, Inc.Non-replicative transduction particles and transduction particle-based reporter systems for detection of acinetobacter baumannii
US11572595B2 (en)2018-12-312023-02-07Roche Molecular Systems, Inc.Non-replicative transduction particles with one or more non-native tail fibers and transduction particle-based reporter systems
EP4007812A1 (en)2019-08-012022-06-08Alnylam Pharmaceuticals, Inc.Serpin family f member 2 (serpinf2) irna compositions and methods of use thereof
EP4007811A2 (en)2019-08-012022-06-08Alnylam Pharmaceuticals, Inc.Carboxypeptidase b2 (cpb2) irna compositions and methods of use thereof
WO2021030522A1 (en)2019-08-132021-02-18Alnylam Pharmaceuticals, Inc.SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
US20220290156A1 (en)2019-08-272022-09-15SanofiCompositions and methods for inhibiting pcsk9
BR112022003860A2 (en)2019-09-032022-08-16Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE LECT2 GENE
CA3147643A1 (en)2019-09-232021-04-01Omega Therapeutics, Inc.Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (hnf4.alpha.) gene expression
WO2021061707A1 (en)2019-09-232021-04-01Omega Therapeutics, Inc.Compositions and methods for modulating apolipoprotein b (apob) gene expression
EP4038189A1 (en)2019-10-042022-08-10Alnylam Pharmaceuticals, Inc.Compositions and methods for silencing ugt1a1 gene expression
EP4041308A1 (en)2019-10-072022-08-17University of Virginia Patent FoundationModulating lymphatic vessels in neurological disease
US20240141358A1 (en)2019-10-182024-05-02Alnylam Pharmaceuticals, Inc.Solute carrier family member irna compositions and methods of use thereof
KR20220084399A (en)2019-10-222022-06-21알닐람 파마슈티칼스 인코포레이티드 Complement component C3 iRNA compositions and methods of use thereof
WO2021087325A1 (en)2019-11-012021-05-06Alnylam Pharmaceuticals, Inc.Compositions and methods for silencing dnajb1-prkaca fusion gene expression
JP2023500661A (en)2019-11-012023-01-10アルナイラム ファーマシューティカルズ, インコーポレイテッド HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
WO2021096763A1 (en)2019-11-132021-05-20Alnylam Pharmaceuticals, Inc.Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
WO2021102373A1 (en)2019-11-222021-05-27Alnylam Pharmaceuticals, Inc.Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
MX2022006433A (en)2019-12-132022-06-23Alnylam Pharmaceuticals IncHuman chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof.
TW202138559A (en)2019-12-162021-10-16美商阿尼拉製藥公司Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
EP4085156B1 (en)2019-12-312023-10-25F. Hoffmann-La Roche AGQuantitative pcr screening of inducible prophage from bacterial isolates
WO2021151079A1 (en)2020-01-242021-07-29University Of Virginia Patent FoundationModulating lymphatic vessels in neurological disease
WO2021154941A1 (en)2020-01-312021-08-05Alnylam Pharmaceuticals, Inc.Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
AU2021220765A1 (en)2020-02-102022-09-01Alnylam Pharmaceuticals, Inc.Compositions and methods for silencing VEGF-A expression
EP4107265A1 (en)2020-02-182022-12-28Alnylam Pharmaceuticals, Inc.Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
IL296109A (en)2020-03-062022-11-01Alnylam Pharmaceuticals Inc Ketohexokinase (khk) IRNA compositions and methods of using them
CA3173528A1 (en)2020-03-112021-09-16Omega Therapeutics, Inc.Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
EP4121534A1 (en)2020-03-182023-01-25Alnylam Pharmaceuticals, Inc.Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
EP4127168A1 (en)2020-03-262023-02-08Alnylam Pharmaceuticals, Inc.Coronavirus irna compositions and methods of use thereof
WO2021202443A2 (en)2020-03-302021-10-07Alnylam Pharmaceucticals, Inc.Compositions and methods for silencing dnajc15 gene expression
JP2023520582A (en)2020-04-062023-05-17アルナイラム ファーマシューティカルズ, インコーポレイテッド Compositions and methods for silencing MYOC expression
EP4133076A1 (en)2020-04-072023-02-15Alnylam Pharmaceuticals, Inc.Angiotensin-converting enzyme 2 (ace2) irna compositions and methods of use thereof
MX2022012561A (en)2020-04-072022-11-07Alnylam Pharmaceuticals IncCompositions and methods for silencing scn9a expression.
WO2021206922A1 (en)2020-04-072021-10-14Alnylam Pharmaceuticals, Inc.Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
BR112022021813A2 (en)2020-04-272023-01-17Alnylam Pharmaceuticals Inc APOLIPOPROTEIN AND (APOE) IRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
BR112022021136A2 (en)2020-04-302022-11-29Alnylam Pharmaceuticals Inc COMPLEMENT FACTOR B IRNA COMPOSITIONS (CFB) AND METHODS OF USE THEREOF
WO2021237097A1 (en)2020-05-212021-11-25Alnylam Pharmaceuticals, Inc.Compositions and methods for inhibiting marc1 gene expression
AU2021292296A1 (en)2020-06-182023-01-19Alnylam Pharmaceuticals, Inc.Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof
EP4217489A1 (en)2020-09-242023-08-02Alnylam Pharmaceuticals, Inc.Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
TW202229552A (en)2020-10-052022-08-01美商艾拉倫製藥股份有限公司G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
JP2023545502A (en)2020-10-162023-10-30サノフイ RNA compositions and methods for inhibiting lipoprotein (A)
EP4229200A1 (en)2020-10-162023-08-23SanofiNovel rna compositions and methods for inhibiting angptl3
EP4232581A1 (en)2020-10-212023-08-30Alnylam Pharmaceuticals, Inc.Methods and compositions for treating primary hyperoxaluria
WO2022087329A1 (en)2020-10-232022-04-28Alnylam Pharmaceuticals, Inc.Mucin 5b (muc5b) irna compositions and methods of use thereof
TW202237841A (en)2020-11-132022-10-01美商艾拉倫製藥股份有限公司Coagulation factor v (f5) irna compositions and methods of use thereof
WO2022119873A1 (en)2020-12-012022-06-09Alnylam Pharmaceuticals, Inc.Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
EP4259795A1 (en)2020-12-082023-10-18Alnylam Pharmaceuticals, Inc.Coagulation factor x (f10) irna compositions and methods of use thereof
WO2022150260A1 (en)2021-01-052022-07-14Alnylam Pharmaceuticals, Inc.COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
CA3210763A1 (en)2021-02-122022-08-18Alnylam Pharmaceuticals, Inc.Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
EP4298220A1 (en)2021-02-252024-01-03Alnylam Pharmaceuticals, Inc.Prion protein (prnp) irna compositions and methods of use thereof
KR20230150844A (en)2021-02-262023-10-31알닐람 파마슈티칼스 인코포레이티드 Ketohexokinase (KHK) iRNA compositions and methods of using the same
WO2022187435A1 (en)2021-03-042022-09-09Alnylam Pharmaceuticals, Inc.Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
EP4305169A1 (en)2021-03-122024-01-17Alnylam Pharmaceuticals, Inc.Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
MX2023011466A (en)2021-03-292024-02-01Alnylam Pharmaceuticals IncHuntingtin (htt) irna agent compositions and methods of use thereof.
EP4314293A1 (en)2021-04-012024-02-07Alnylam Pharmaceuticals, Inc.Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
EP4330392A1 (en)2021-04-262024-03-06Alnylam Pharmaceuticals, Inc.Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof
WO2022232343A1 (en)2021-04-292022-11-03Alnylam Pharmaceuticals, Inc.Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
EP4341401A1 (en)2021-05-182024-03-27Alnylam Pharmaceuticals, Inc.Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
JP2024522996A (en)2021-06-022024-06-25アルナイラム ファーマシューティカルズ, インコーポレイテッド Patatin-like phospholipase domain-containing 3 (PNPLA3) iRNA compositions and methods of use thereof
CA3221245A1 (en)2021-06-042022-12-08Alnylam Pharmaceuticals, Inc.Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof
EP4351541A2 (en)2021-06-082024-04-17Alnylam Pharmaceuticals, Inc.Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
EP4363580A1 (en)2021-06-302024-05-08Alnylam Pharmaceuticals, Inc.Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
EP4367242A2 (en)2021-07-072024-05-15Omega Therapeutics, Inc.Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
EP4373934A1 (en)2021-07-192024-05-29Alnylam Pharmaceuticals, Inc.Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
TW202421169A (en)2021-07-212024-06-01美商艾拉倫製藥股份有限公司Metabolic disorder-associated target gene irna compositions and methods of use thereof
IL309905A (en)2021-07-232024-03-01Alnylam Pharmaceuticals IncBeta-catenin (ctnnb1) irna compositions and methods of use thereof
JP2024529437A (en)2021-07-292024-08-06アルナイラム ファーマシューティカルズ, インコーポレイテッド 3-hydroxy-3-methylglutaric-coa reductase (hmgcr) iRNA compositions and methods of use thereof
CN117795074A (en)2021-08-032024-03-29阿尔尼拉姆医药品有限公司 Transthyretin (TTR) iRNA compositions and methods of use
MX2024001445A (en)2021-08-042024-02-27Alnylam Pharmaceuticals Inc COMPOSITIONS OF INTERFERENCE RIBONUCLEIC ACID (RNAI) AND METHODS FOR SILENCERING ANGIOTENSINOGEN (AGT).
CN118076737A (en)2021-08-132024-05-24阿尔尼拉姆医药品有限公司 Factor XII (F12) iRNA compositions and methods of use thereof
WO2023034837A2 (en)2021-08-312023-03-09Alnylam Pharmaceuticals, Inc.Cell death-inducing dffa-like effector b (cideb) irna compositions and methods of use thereof
EP4401742A2 (en)2021-09-172024-07-24Alnylam Pharmaceuticals, Inc.Irna compositions and methods for silencing complement component 3 (c3)
IL311454A (en)2021-09-202024-05-01Alnylam Pharmaceuticals Inc Inhibin subunit E (INHBE) modulator compositions and methods of using them
WO2023064530A1 (en)2021-10-152023-04-20Alnylam Pharmaceuticals, Inc.Extra-hepatic delivery irna compositions and methods of use thereof
CA3234636A1 (en)2021-10-292023-05-04Alnylam Pharmaceuticals, Inc.Complement factor b (cfb) irna compositions and methods of use thereof
WO2023076450A2 (en)2021-10-292023-05-04Alnylam Pharmaceuticals, Inc.HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
WO2023141314A2 (en)2022-01-242023-07-27Alnylam Pharmaceuticals, Inc.Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
MA71735A (en)2022-09-152025-05-30Regeneron Pharmaceuticals, Inc. 17B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) RNAI COMPOSITIONS AND METHODS OF USE THEREOF
WO2024243438A2 (en)2023-05-232024-11-28Omega Therapeutics, Inc.Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
WO2025034422A1 (en)2023-08-042025-02-13Alnylam Pharmaceuticals, Inc.Methods and compositions for treating ctnnb1-associated disorders
WO2025064660A2 (en)2023-09-212025-03-27Alnylam Pharmaceuticals, Inc.Activin a receptor type 1c (acvr1c) irna compositions and methods of use thereof
WO2025072672A2 (en)2023-09-272025-04-03Judo Bio, Inc.Slc6a19-targeting modulatory nucleic acid agents
US20250313840A1 (en)2024-03-202025-10-09Vertex Pharmaceuticals IncorporatedMucin-5b (muc5b) targeted sirna and antisense oligonucleotides and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US5434070A (en)*1989-02-241995-07-18The University Of Medicine And Dentistry Of New JerseyReverse transcriptases from Escherichia coli and Myxococcus xanthus
US5436141A (en)*1989-02-241995-07-25University Of Medicine And Dentistry Of New JerseyMethod for synthesizing stable single-stranded CDNA in eukaryotes by means of a bacterial retron and products
CA2073630C (en)*1991-08-302007-12-11Atsushi OhshimaMethod for synthesizing single-stranded stem-loop dnas, the products and uses therefor
AU672689B2 (en)*1991-08-301996-10-10University Of Medicine And Dentistry Of New JerseyOver expression of single-stranded molecules
RU94046425A (en)*1992-07-021997-03-20ХайбрайдонSelf-stabilized oligonucleotide and method of genetic expression inhibition
WO1994013689A1 (en)*1992-12-091994-06-23Miller Jeffrey EMETHODS AND COMPOSITIONS FOR cDNA SYNTHESIS
FR2703053B1 (en)*1993-03-261995-06-16Genset Sa STAPLE AND SEMI-STAPLE OLIGONUCLEOTIDES, PREPARATION METHOD AND APPLICATIONS.
CA2193487A1 (en)*1994-06-221995-12-28Jeffrey E. MillerMethods and compositions for cdna synthesis

Also Published As

Publication numberPublication date
JP2002527061A (en)2002-08-27
CA2346155A1 (en)2000-04-20
AU6430599A (en)2000-05-01
IL142490A0 (en)2002-03-10
MXPA01003642A (en)2003-07-21
WO2000022113A1 (en)2000-04-20
WO2000022113A9 (en)2000-08-24
KR20010099682A (en)2001-11-09
EP1117776A1 (en)2001-07-25

Similar Documents

PublicationPublication DateTitle
BR9914772A (en) Set of genetic elements, vector, host cell, set for the production of a nucleic acid sequence, method for in vivo or in vitro production of a nucleic acid sequence, cdna transcription, inhibitor nucleic acid molecule, mrna transcription, heteroduplex molecule and pharmaceutical composition
Cladaras et al.DNA sequence of the early E3 transcription unit of adenovirus 5
Dunn et al.Phenobarbital-inducible aldehyde dehydrogenase in the rat: cDNA sequence and regulation of the mRNA by phenobarbital in responsive rats
Marbaix et al.Absence of polyadenylate segment in globin messenger RNA accelerates its degradation in Xenopus oocytes.
Lin et al.Variants of N-acetyltransferase NAT1 and a case-control study of colorectal adenomas
Tolstoshev et al.Procollagen production and procollagen messenger RNA levels and activity in human lung fibroblasts during periods of rapid and stationary growth.
WO1998042729A3 (en)Steroid sulfamates, method for the production and use thereof
Henikoff et al.Multiple purine pathway enzyme activities are encoded at a single genetic locus in Drosophila.
Butcher et al.Genomic organization of human arylamine N-acetyltransferase Type I reveals alternative promoters that generate different 5′-UTR splice variants with altered translational activities
Barone et al.Cell type specific trans‐acting factors are involved in alternative splicing of human fibronectin pre‐mRNA.
CN114540473A (en)Novel nucleic acid sequencing system
Bracey et al.Changes in translational yield regulate tissue-specific expression of beta-glucuronidase.
Lusis et al.Trans-acting temporal locus within the beta-glucuronidase gene complex.
Cheng et al.Isolation and characterization of modified globin messenger ribonucleic acid from erythropoietic mouse spleen
Zanger et al.Tri‐allelic haplotypes determine and differentiate functionally Normal allele CYP2D6* 2 and impaired allele CYP2D6* 41
JPH04502557A (en) Method for detecting small cell carcinoma, acyl-peptide hydrolase and its encoding sequence
Matsutani et al.Chick endogenous lectin enhances chondrogenesis of cultured chick limb bud cells
Allemann et al.A hybrid of bovine pancreatic ribonuclease and human angiogenin: an external loop as a module controlling substrate specificity?
US4325832A (en)Enzyme reference composition
Eichler et al.A “molten globule” of Torpedo acetylcholinesterase undergoes thiol-disulfide exchange.
Chang et al.The mechanism of the irreversible inhibition ofrat liver phenylalanine hydroxylase due to treatment with p-chlorophenylalanine. The lack of effect on turnover of phenylalanine hydroxylase.
Manenti et al.Effects of phenobarbital and 1, 4-bis [2-(3, 5-dichloropyridyloxy)] benzene on differentiated functions in mouse liver
Richards et al.Restriction enzyme mapping and heteroduplex analysis of the rat milk protein cDNA clones.
RushResolution and purification of two monomeric butyrylcholinesterases from rabbit liver.
CN110156703A (en) Phenazine derivatives as TrxR1 inhibitors, intermediates and preparation methods and uses thereof

Legal Events

DateCodeTitleDescription
B08FApplication dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text:REFERENTE A 5A, 6A, 7A E 8A ANUIDADES.

B08KPatent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text:REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.


[8]ページ先頭

©2009-2025 Movatter.jp